Cor Vasa 2006, 48(12):441-446 | DOI: 10.33678/cor.2006.138

Left ventricular remodelling adaptation or maladaptation?

Radovan Jirmář1,*, Václav Pelouch2, Petr Widimský1
1 III. interní-kardiologická klinika, Fakultní nemocnice Královské Vinohrady a 3. lékařská fakulta Univerzity Karlovy
2 Ústav lékařské chemie a biochemie, 2. lékařská fakulta Univerzity Karlovy, Praha, Česká republika

The paper summarizes current concepts regarding the development, progression and clinical relevance of left ventricular remodelling at cellular and subcellular levels. Also addressed are some signal processes critical for the development of left ventricular remodelling and optional therapeutic interventions. Special attention is given to changes occurring in the myocardial interstitium during the process of remodelling.

Keywords: Cellular and subcellular left ventricular remodelling; Cellular signal processes; Maladaptation; Myocardial interstitium

Published: December 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jirmář R, Pelouch V, Widimský P. Left ventricular remodelling adaptation or maladaptation? Cor Vasa. 2006;48(12):441-446. doi: 10.33678/cor.2006.138.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985;57:84-95. Go to original source...
    2. Pfeffer MA, Braunwald E. Ventricular remodelling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990;81:1161-72. Go to original source...
    3. Jirmáfi R, Pelouch V. The role of myocardial interstitium in the left ventricular remodelling after an acute myocardial infarction. Cor Vasa 1993;35;206-9.
    4. Pelouch V, Jirmáfi R. Biochemical characteristics of cardiac collagen and its role in ventricular remodelling following infarction. Physiol Res 1993;42:283-92.
    5. Jirmáfi R, Pelouch V. Úloha myokardiálního intersticia v procesu remodelace levé komory po akutní infarktu myokardu. Cor Vasa 1993;35:206-9.
    6. Grossman W, Jones D, McLaurin L. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 1975;56:56-64. Go to original source... Go to PubMed...
    7. Sadoshima K, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin-II mediates stretch-induced hypertrophy of cardiac myocytes in vitro of cardiac myocytes in vitro. Cell 1993;75:977-84. Go to original source... Go to PubMed...
    8. Baines CP, Molkentin JD. STRESS signalling pathways that modulate cardiac myocyte apoptosis. J Mol Cell Cardiol 2005;38:47-62. Go to original source... Go to PubMed...
    9. Bradham WS, Bozkurt B, Gunasinghe H, et al. Tumor necrosis factor-alpha and myocardial remodelling in progression of heart failure: a current perspective. Cardiovasc Res 2002;53:822-30. Go to original source... Go to PubMed...
    10. Esposito G, Rapacciuolo A, Prasad SVN, et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 2002;105:85-92. Go to original source... Go to PubMed...
    11. Heymans S, Schroen B, Vermeersch P, et al. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 2005;112:1136-44. Go to original source... Go to PubMed...
    12. Sundstrom J, Evans JC, Benjamin EJ, et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 2004;109:2850-6. Go to original source... Go to PubMed...
    13. Bueno OF, De Windt LJ, Kimball TR, et al. The MEK1-ERK 1/2 signalling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 2000; 19:6341-50. Go to original source... Go to PubMed...
    14. Modesti PA, Vanni S, Bertolozzi I, et al. Early sequence of cardiac adaptations and growth factor formation in pressure- and volume-overload hypertrophy. Am J Physiol Heart Circ Physiol 2000;279:H976-H985. Go to original source... Go to PubMed...
    15. Sutton MSJ, Pfeffer MA, Moye L, et al. Cardiovascular death and left ventricular remodelling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation 1997;96:3294-9. Go to original source...
    16. Olivetti G, Capasso JM, Sonnenblick EH, et al. Side-to-side slippage of myocytes participates in ventricular wall remodelling acutely after myocardial infarction in rats. Circ Res 1990;67:23-34. Go to original source...
    17. Jirmáfi R, Pelouch V, Widimsky P, et al. Influence of primary coronary intervention on myocardial collagen metabolism and left ventricle remodelling predicted by collagen metabolism markers. Intern Heart J 2005; 46:949-59. Go to original source...
    18. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure. Lancet 1999;353:2001-7. Go to original source...
    19. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomized trial. Lancet 1999;353:9-13. Go to original source...
    20. Mitchell GF, Lamas GA, Vaughan DE, Pfeffer MA. Left ventricular remodelling in the year after first anterior myocardial infarction: a quantitative analysis of contractile segment lengths and ventricular shape. J Am Coll Cardiol 1992;19:1136-44. Go to original source...
    21. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. New Engl J Med 1984; 311:819-23. Go to original source... Go to PubMed...
    22. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. Circulation 1990;82:1724-9. Go to original source... Go to PubMed...
    23. Vantrimpont P, Rouleau JL, Ciampi A, et al. Two-year course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) study. Eur Heart J 1998;19:1552-63. Go to original source... Go to PubMed...
    24. Sawyer DB, Siwik D, Xiaol L, et al. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 2002;34:379-88. Go to original source... Go to PubMed...
    25. Torre-Amione G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996;27:1201-6. Go to original source... Go to PubMed...
    26. Mann DL. Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu Rev Physiol 2003;65:81-101. Go to original source... Go to PubMed...
    27. Thackray S, Easthaugh J, Freemantle N, et al. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure- a meta-regression analysis. Eur J Heart Fail 2002;4:515-29. Go to original source... Go to PubMed...
    28. Teerlink JR, McMurray JV, Bourge RC, et al. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). Am Heart J 2005;150:46-53. Go to original source... Go to PubMed...
    29. Kuster GM, Kotlyar E, Rude MK, et al. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation 2005;111:420-7. Go to original source... Go to PubMed...
    30. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Immunol 1994;26:809-20. Go to original source... Go to PubMed...
    31. Pitt B, Williams G, Remme W, et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001; 15:79-87. Go to original source... Go to PubMed...
    32. Remme JW, Rieger G, Hildebrandt P, et al. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). Cardiovasc Drugs Ther 2004;18:57-66. Go to original source... Go to PubMed...
    33. Hayashidani S, Tsutsui H, Shiomi T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodelling and failure after experimental myocardial infarction. Circulation 2002;105:868-73. Go to original source... Go to PubMed...
    34. D'Ascia C, Cittadini A, Monti MG, et al. Effects of biventricular pacing on interstitial remodelling, tumor necrosis factor-α expression, and apoptotic death in failing human myocardium. Eur Heart J 2006;27:201-6. Go to original source... Go to PubMed...
    35. Dib N, Michler RE, Pagani FD, et al. Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy: four-year follow-up. Circulation 2005;112:1748-55. Go to original source... Go to PubMed...
    36. Janssens S, Dubois C, Bogaert J, et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 2006;367: 113-21. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes